Scalper1 News
RBC Capital Markets raised its price target on BioMarin Pharmaceuticals (BMRN) Wednesday after a meeting with management raised hope for approval of its muscular-dystrophy drug. Analyst Michael Yee lifted his target on BioMarin stock to 155 from 145, assigning a 65% probability of approval to drisapersen, the Duchenne muscular dystrophy (DMD) drug that is due for an FDA decision by Dec. 27. Among his reasons for confidence: “totality of three Scalper1 News
Scalper1 News